Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 6,437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Completed Not applicable Interventional

CoQ10 Biomarker Trial

NCT01408680
View directory record Official record
Conditions
Oxidative Stress, Inflammation, Endothelial Dysfunction
Interventions
Coenzyme Q10, Placebo
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 25, 2026, 5:05 PM EDT
Withdrawn Phase 4 Interventional

Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease

NCT00573547
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Oct 25, 2026, 5:05 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Jackson Heart Study of Cardiovascular Disease Among African Americans

NCT00005485
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Coronary Disease, Hypertension, Cerebrovascular Disorders
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
35 Years to 84 Years
Enrollment
5,306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

NCT04119843
View directory record Official record
Conditions
Known or Suspected Focal Liver Lesions, Severe Renal Impairment
Interventions
Mangoral
Drug
Lead sponsor
Ascelia Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Not applicable Interventional Results available

HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients

NCT03500315
View directory record Official record
Conditions
Hiv
Interventions
HIV D+/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)

NCT04702997
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Bardoxolone methyl oral capsule, Placebo oral capsule
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
La Mesa, California • Arvada, Colorado • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320
View directory record Official record
Conditions
Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT03096080
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Recessive
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
5 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome

NCT04169776
View directory record Official record
Conditions
Idiopathic Nephrotic Syndrome, Frequently Relapsing Nephrotic Syndrome
Interventions
Transcutaneous Auricular Vagus Nerve (taVNS) stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
DCR-PHXC, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension

NCT03196076
View directory record Official record
Conditions
Chronic Kidney Diseases, Cystic Kidney Disease
Interventions
Perflutren Lipid microsphere
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

NCT03027960
View directory record Official record
Conditions
Heart Failure, Type II; Diabetes
Interventions
Empagliflozin, Placebo Oral Capsule
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 25, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

NCT05361720
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Cabozantinib, Ipilimumab, Nivolumab
Drug · Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Duarte, California • Orange, California • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

NCT07128680
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Dietary Supplement · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis

NCT00275613
View directory record Official record
Conditions
Glomerulonephritis, Membranoproliferative
Interventions
Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease

NCT02539160
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 25, 2026, 5:05 PM EDT
Withdrawn Phase 4 Interventional

Acthar on Proteinuria in IgA Nephropathy Patients

NCT02382523
View directory record Official record
Conditions
IgA Nephropathy, Proteinuria
Interventions
Acthar 80 unit injection
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 25, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional

Diuretic Tuner Clinical Decision Support

NCT04759274
View directory record Official record
Conditions
Edema, Hypervolemia, Chronic Kidney Diseases, Nephrotic Syndrome
Interventions
Diuretic Tuner
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 25, 2026, 5:05 PM EDT
Withdrawn No phase listed Observational

Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)

NCT04782297
View directory record Official record
Conditions
CKD, ESRD
Interventions
Long term hemodialysis catheter
Device
Lead sponsor
Medical Components, Inc dba MedComp
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 25, 2026, 5:05 PM EDT
Terminated Phase 1Phase 2 Interventional

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

NCT03637803
View directory record Official record
Conditions
Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
Interventions
MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Drug
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 25, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

NCT00045279
View directory record Official record
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 25, 2026, 5:05 PM EDT
Active, not recruiting Not applicable Interventional

Dietary Intervention to Improve Kidney Transplant Outcomes

NCT05449496
View directory record Official record
Conditions
Kidney Transplant; Complications, Kidney Diseases, Transplant;Failure,Kidney, Diabetes, Hypertension, Obesity, Diet, Healthy, Lifestyle, Healthy
Interventions
Dietary Education Curriculum
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 25, 2026, 5:05 PM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

NCT06984341
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine, Rimiducid
Biological · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
2
States / cities
Birmingham, Alabama • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 25, 2026, 5:05 PM EDT